# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implication...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics. First...
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gai...
Pfizer and Moderna continue their legal battle over COVID-19 vaccine patents following a mixed ruling by London's High Cour...
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractor...
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months ...
HC Wainwright & Co. analyst Robert Burns reiterates BioNTech (NASDAQ:BNTX) with a Buy and maintains $113 price target.